Vigil Neuroscience, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
SCHEDULE: Vigil Neuroscience Acquired by Sanofi
Vigil Neuroscience, Inc. has been acquired by Sanofi, with shareholders receiving $8.00 cash plus a $2.00 contingent value right per share.
Vida Ventures, through its entities Vida Ventures III, L.P. and Vida Ventures III-A, L.P., has significantly reduced its beneficial ownership in Vigil Neuroscience, Inc. by selling over 1.2 million shares of common stock for approximately $9.5 million.
Vida Ventures, a key institutional investor, has filed an Amendment No. 2 to its Schedule 13D, disclosing a substantial reduction in its beneficial ownership of Vigil Neuroscience, Inc. common stock.
SCHEDULE 13D/A: Northpond Ventures Divests Entire Stake in Vigil Neuroscience, Ceasing Major Shareholder Status
Northpond Ventures and its affiliates have reported the sale of their entire beneficial ownership in Vigil Neuroscience, Inc., effective May 22, 2025, no longer holding more than five percent of the company's common stock.